The "Antibody Contract Development & Manufacturing Organization Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering.
The global antibody contract development and manufacturing organization (CDMO) market is poised for substantial growth, with its value estimated at USD 21.1 billion in 2024 and projected to soar to USD 45.8 billion by 2033. This represents a CAGR of 9.38% from 2025 to 2033, driven by a surge in demand for monoclonal antibodies and biologics.
The industry is benefitting from increased outsourcing in response to rapid advancements in antibody engineering, high-throughput screening, and stringent regulatory demands. Such factors, combined with cost effectiveness within CDMO services, are compelling biopharmaceutical manufacturers to outsource production, propelling market growth.
Monoclonal antibodies (mAbs) and biologics are seeing high demand due to the rising prevalence of chronic and autoimmune conditions like cancer, rheumatoid arthritis, and multiple sclerosis. These therapeutic solutions offer high specificity and efficacy with fewer side effects compared to traditional drugs, making them the preferred choice. Advances in biotechnology and antibody engineering have broadened their therapeutic applications. Additionally, increased patient awareness, favorable reimbursement policies, and the enhancement of healthcare infrastructure in emerging markets continue to fuel adoption globally.
The expanding pipelines in oncology and autoimmune disease treatments highlight the growing need for specialized CDMO services. As drugs progress through various clinical and commercial phases, CDMOs become crucial in ensuring efficient, scalable, and compliant antibody production.
Regulatory agencies such as the FDA and EMA are imposing strict guidelines on the development and manufacturing of biologics, including mAbs. Compliance with Good Manufacturing Practices (GMP) and safety standards is mandatory to assure product efficacy and safety, driving biopharmaceutical companies towards experienced CDMOs capable of meeting these requirements efficiently.
Global Antibody CDMO Market Report Segmentation
This report provides a comprehensive analysis of revenue growth at global, regional, and country levels, with an evaluation of industry trends from 2021 to 2033 across various segments.
Product Outlook (Revenue, USD Million, 2021-2033):
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Bispecific/ Multispecific Antibodies
- Polyclonal Antibodies
- Others
Service Outlook (Revenue, USD Million, 2021-2033):
- Contract Development
- Contract Manufacturing
- Packaging and Labelling
- Regulatory Affairs
- Logistics & Storage
- Others
Source Outlook (Revenue, USD Million, 2021-2033):
- Mammalian
- Microbial
Workflow Outlook (Revenue, USD Million, 2021-2033):
- Clinical
- Commercial
Therapeutic Area Outlook (Revenue, USD Million, 2021-2033):
- Oncology
- Infectious Diseases
- Neurological Disorders
- Cardiovascular Disease
- Metabolic Disorders
- Autoimmune Diseases
- Respiratory Diseases
- Ophthalmology
- Gastrointestinal Disorders
- Others
End-use Outlook (Revenue, USD Million, 2021-2033):
- Large Pharma & Biotech Companies
- Small & Mid-sized Pharma & Biotech Companies
- Others
Regional Outlook (Revenue, USD Million, 2021-2033):
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Why You Should Buy This Report:
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Report Deliverables:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 120 |
| Forecast Period | 2024-2033 |
| Estimated Market Value (USD) in 2024 | $21.1 Billion |
| Forecasted Market Value (USD) by 2033 | $45.8 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
The companies profiled in this Antibody Contract Development & Manufacturing Organization market report include:
- Lonza Group
- Catalent, Inc.
- Samsung Biologics
- WuXi Biologics
- AGC Biologics
- AbbVie Inc.
- Boehringer Ingelheim International GmbH
- Charles River Laboratories
- FUJIFILM Holdings Corporation
- mAbxience
For more information about this report visit https://www.researchandmarkets.com/r/dx5ipr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251126140748/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
